News Agency
Men's Weekly

Ascentage Pharma Signs Option Agreement with Takeda to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)

  • Written by PR Newswire
Ascentage Pharma Signs Option Agreement with Takeda to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)
  • Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other than China and a few other areas.
  • Ascentage Pharma to receive an option payment of 100 million USD upon closing and be eligible for an option exercise fee and additional potential milestones of up to approximately 1.2 billion USD, and...

Read more: Ascentage Pharma Signs Option Agreement with Takeda to Enter into Exclusive Global License for...

3PL Companies Powering Efficient Logistics And Scalable Business Growth

Behind every smooth online order and timely delivery, there’s often an invisible engine working tirelessly in the background. That engine is powered by 3PL companies, quietly orchestrating storage, packing, and shipping so businesses can focus on what they do best... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion